Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions, The FDA confirmed that this sole Phase III trial would secure
Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions,The FDA confirmed that this sole Phase III trial would secure Batten-1
This press release updates an earlier issuance with updated language throughout.Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor
Lyon, France - 12 April 2023 - 6pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating
From 22 to 26 February 2023 in Orlando, Florida Presentation of preclinical data demonstrating how Batten-1 drastically reduces the buildup of toxic glycosphingolipids in Batten disease and a poster